Skip to content

Relationship of Nutritional Status to Chemotherapy Treatment Completion and Outcomes in Cancer Patients

Evaluate the Relationship of Nutritional Status to Chemotherapy Treatment Completion Rates and Outcomes in Real-life Conditions in Patients With Metastatic and Non-metastatic Gastric, Colon, and Lung Cancer.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07059598
Enrollment
209
Registered
2025-07-11
Start date
2022-08-12
Completion date
2025-03-01
Last updated
2025-07-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer-related Malnutrition

Brief summary

This non-interventional, prospective, non-drug observational study is designed to observe the effect of the nutritional status of metastatic and non-metastatic gastric, colon and lung cancer patients on their cancer chemotherapy treatment completion rates.

Interventions

None listed

Sponsors

Abbott Nutrition
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Subject or subject's legally acceptable representative (LAR) has voluntarily signed and dated an ICF approved by an IEC, or any other applicable privacy authorization prior to any participation in the study. * Ambulatory and inpatient subject. * Subject recently (within the last month) or newly diagnosed to have metastatic or non-metastatic gastric, colon and lung cancer. * Subject is recently receiving chemotherapy or recently prescribed to begin chemotherapy treatment per standard of care (within the last month) or candidates who will receive chemotherapy. * Subject has a life expectancy greater than 6 months.

Exclusion criteria

* Subject has known dementia, brain metastases, eating disorders, history of significant neurological or psychiatric disorder, any other psychological condition, serious illness or medical condition that may interfere with study completion. * Subject has malignant tumors other than treated DCIS, fully treated non-melanoma skin cancer, curatively resected in-situ cervical cancer or other curative treated tumors (except stomach, colon and lung cancer) for \> 5 years. * Subject has bone marrow metastasis. * Subject is lactating. * Subject is participating in another study that has not been approved as a concomitant study.

Design outcomes

Primary

MeasureTime frameDescription
PG-SGABaseline to week 24Healthcare Professional completed assessment resulting in score where A = Well Nourished, B = Moderately Malnourished, and C = Severely Malnourished
RMAPPBaseline to week 24A tool to screen patients for risk of malnutrition and/or sarcopenia

Secondary

MeasureTime frameDescription
HeightBaselineHeight in CM
Calf CircumferenceBaseline to 24 weeksChange in calf circumference
Fat Free Mass IndexBaseline to week 24Evaluate Muscle Mass in relation to height and weight
Body Mass IndexBaseline to week 24As calculated from height and weight
Handgrip StrengthBaseline to 24 weeksChange in handgrip dynamometer as measured in kilograms
Walking SpeedBaseline to 24 weeksChange in Gait Speed over 6 meter walk
EORTC QLQ-C30Baseline to 12 monthsQuestionnaire with 28 questions from 1 to 4 with higher number is more favorable and 2 overall score questions from very poor to excellent
WeightBaseline to 24 weeksChange in weight

Other

MeasureTime frameDescription
HealthCare Resource UtilizationBaseline to 12 monthsNumber of unplanned inpatient hospitalizations, outpatient clinic visits, emergency department visits

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026